Impulse Control Disorders in Parkinson’s disease


Aleksander Hagen Erga
Keywords: nevrologi, Parkinson, Parkinson's, impulskontroll, psykose, ParkWest


Background Parkinson’s disease (PD) is a common neurodegenerative disorder, affecting 1% of the population aged over 60. PD is characterized by the presence of several motor symptoms, which often are accompanied by a range of neuropsychiatric and non-motor symptoms. Impulse control disorders (ICDs) include a range of behavioral disorders, frequently occurring as a complication of PD. However, the epidemiology and risk profile for developing ICDs in patients with PD has not been fully examined. Objectives The overall aim of this thesis was to describe the epidemiology, genetic risk and long-term trajectory of ICDs in PD. Methods All papers of this thesis are based on the Norwegian ParkWest study, a prospective, population-based, multicentre, longitudinal cohort study of patients with newly diagnosed PD. In this study, 212 patients were followed prospectively by experienced movement disorders specialists. A large cohort of non-PD subjects was included as a control group. Assessment of ICDs was first introduced five years after baseline assessment. Associated features and risk factors of ICDs were explored in both cross-sectional and longitudinal analyses. Associated genetic polymorphisms were explored based on already gathered whole-exome sequencing data from the Norwegian ParkWest study. Results At study start, patients with PD had about 3-fold increased odds of having any ICD and more than 7-fold increased odds of multiple ICDs compared with matched normal controls. Patients treated with dopamine agonist, but not other dopaminergic drugs, had even higher odds of having an ICD compared with controls. ICD status in patients was independently associated with dopamine agonist treatment and depressive symptoms. In additional analyses on the PD cohort, we did not find any association between ICD status and presence of psychotic symptoms. Presence of ICDs in patients with PD at study start was associated with 11 single-nucleotide polymorphisms across nine genes. In addition to already identified polymorphisms, we found a novel polymorphism in the DRD1-gene.

Author Biography

Aleksander Hagen Erga

Associate Professor
Department of Biological and Medical Psychology
University of Bergen


Parkinson J. An essay on the shaking palsy. London: Sherwood, Neely and Jones; 1817.

Charcot JM. 'On Parkinson's disease. lectures on Diseases of the Nercous System Delivered at the Salpêtrière [trans. Sigerson G.]. London: New Sydenham Society; 1872:129-156.

Pringsheim T, Jette N, Frolkis A, Steeves TD. The prevalence of Parkinson's disease: a systematic review and meta-analysis. Mov Disord. Nov 2014;29(13):1583-1590.

de Lau LML, Breteler MMB. Epidemiology of Parkinson's disease. The Lancet Neurology. 2006;5(6):525-535.

Alves G, Muller B, Herlofson K, et al. Incidence of Parkinson's disease in Norway: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry. Aug 2009;80(8):851-857.

von Campenhausen S, Bornschein B, Wick R, et al. Prevalence and incidence of Parkinson's disease in Europe. Eur Neuropsychopharmacol. Aug 2005;15(4):473-490.

Kalia LV, Lang AE. Parkinson's disease. The Lancet. 2015;386(9996):896-912.

Delamarre A, Meissner WG. Epidemiology, environmental risk factors and genetics of Parkinson's disease. Press. Med. 2017;46:175-181.

Caminiti SP, Presotto L, Baroncini D, et al. Axonal damage and loss of connectivity in nigrostriatal and mesolimbic dopamine pathways in early Parkinson's disease. Neuroimage Clin. 2017;14:734-740.

Lezak MD, Howieson DB, Bigler ED, Tranel D. Neuropsychological Assessment - fifth edition. New York: Oxford University Press; 2012.

Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci. Oct 1989;12(10):366-375.

Dickson DW. Parkinson's disease and parkinsonism: neuropathology. Cold Spring Harb Perspect Med. Aug 1 2012;2(8).

Cropley VL, Fujita M, Innis RB, Nathan PJ. Molecular imaging of the dopaminergic system and its association with human cognitive function. Biol Psychiatry. May 15 2006;59(10):898-907.

Marek K, Seibyl J, Zoghbi S, et al. [ 123 I]P-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi- Parkinson's disease. Neurology. 1996;46(1).

Brooks DJ, Piccini P. Imaging in Parkinson's disease: the role of monoamines in behavior. Biol Psychiatry. May 15 2006;59(10):908- 918.

Surguchev AA, Surguchov A. Synucleins and Gene Expression: Ramblers in a Crowd or Cops Regulating Traffic? Front Mol Neurosci. 2017;10:224.

Braak H, Rub U, Gai WP, Del Tredici K. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm. May 2003;110(5):517-536.

Michel PP, Hirsch EC, Hunot S. Understanding Dopaminergic Cell Death Pathways in Parkinson Disease. Neuron. May 18 2016;90(4):675-691.

Gaare JJ, Nido GS, Sztromwasser P, et al. Rare genetic variation in mitochondrial pathways influences the risk for Parkinson's disease. Mov Disord. Oct 2018;33(10):1591-1600.

Diederich NJ, Goldman JG, Stebbins GT, Goetz CG. Failing as doorman and disc jockey at the same time: Amygdalar dysfunction in Parkinson's disease. Mov Disord. Jan 2016;31(1):11-22.

Obeso JA, Rodriguez-Oroz MC, Goetz CG, et al. Missing pieces in the Parkinson's disease puzzle. Nat Med. Jun 2010;16(6):653-661.

Chang D, Nalls MA, Hallgrimsdottir IB, et al. A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci. Nat Genet. Oct 2017;49(10):1511-1516.

Singleton A, Hardy J. The Evolution of Genetics: Alzheimer's and Parkinson's Diseases. Neuron. Jun 15 2016;90(6):1154-1163.

Nalls MA, Blauwendraat C, Vallerga CL, et al. Parkinson's disease genetics: identifying novel risk loci, providing causal insights and improving estimates of heritable risk. (preprint). 2018.

Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol. May 2009;8(5):464-474.

Aarsland D, Bronnick K, Alves G, et al. The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson's disease. J Neurol Neurosurg Psychiatry. Aug 2009;80(8):928-930.

Ehgoetz Martens KA, Lewis SJ. Pathology of behavior in PD: What is known and what is not? J Neurol Sci. Mar 15 2017;374:9-16.

Erro R, Picillo M, Vitale C, et al. Non-motor symptoms in early Parkinson's disease: a 2-year follow-up study on previously untreated patients. J Neurol Neurosurg Psychiatry. 2013;84(1):14-17.

Leiknes I, Tysnes OB, Aarsland D, Larsen JP. Caregiver distress associated with neuropsychiatric problems in patients with early Parkinson's disease: the Norwegian ParkWest study. Acta Neurol Scand. Dec 2010;122(6):418-424.

Thommessen B, Aarsland D, Braekhus A, Oksengaard AR, K. E, Laake K. The psychsocial burden of spouses of the elderly with stroke, dementia and Parkinson's disease. Int J Geriatr Psychiatry. 2002;17:78- 84.

Aarsland D, Larsen JP, Lim NG, et al. Range of neuropsychiatric disturbances in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 1999;67:492-496.

Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord. Jan 30 2008;23(2):183-189; quiz 313.

Dissanayaka NN, Sellbach A, Matheson S, et al. Anxiety disorders in Parkinson's disease: prevalence and risk factors. Mov Disord. May 15 2010;25(7):838-845.

Weintraub D, Simuni T, Caspell-Garcia C, et al. Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. Mov Disord. Jun 2015;30(7):919-927.

Pedersen KF, Alves G, Bronnick K, Aarsland D, Tysnes OB, Larsen JP. Apathy in drug-naive patients with incident Parkinson's disease: the Norwegian ParkWest study. J Neurol. Feb 2010;257(2):217-223.

Corallo F, De Cola MC, Lo Buono V, Di Lorenzo G, Bramanti P, Marino S. Observational study of quality of life of Parkinson's patients and their caregivers. Psychogeriatrics. Mar 2017;17(2):97-102.

Aarsland D, Bronnick K, Larsen JP, Tysnes OB, Alves G, Norwegian ParkWest Study G. Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. Neurology. Mar 31 2009;72(13):1121-1126.

de la Riva P, Smith K, Xie SX, Weintraub D. Course of psychiatric symptoms and global cognition in early Parkinson disease. Neurology. Sep 16 2014;83(12):1096-1103.

Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8- year prospective study. Arch Neurol. Mar 2003;60(3):387-392.

Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord. Apr 30 2008;23(6):837-844.

Pigott K, Rick J, Xie SX, et al. Longitudinal study of normal cognition in Parkinson disease. Neurology. Oct 13 2015;85(15):1276-1282.

Aarsland D, Andersen K, Larsen JP, et al. The rate of cognitive decline in Parkinson disease. Arch Neurol. Dec 2004;61(12):1906-1911.

Pedersen KF, Larsen JP, Tysnes OB, Alves G. Prognosis of mild cognitive impairment in early Parkinson disease: the Norwegian ParkWest study. JAMA Neurol. May 2013;70(5):580-586.

Irwin DJ, White MT, Toledo JB, et al. Neuropathologic substrates of Parkinson disease dementia. Ann Neurol. Oct 2012;72(4):587-598.

Litvan I, Goldman JG, Troster AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord. Mar 2012;27(3):349-356.

Janvin CC, Aarsland D, Larsen JP. Cognitive predictors of dementia in Parkinson's disease: a community-based, 4-year longitudinal study. J Geriatr Psychiatry Neurol. Sep 2005;18(3):149-154.

Aarsland D, Bronnick K, Williams-Gray C, et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology. Sep 21 2010;75(12):1062-1069.

Bronnick K, Emre M, Lane R, Tekin S, Aarsland D. Profile of cognitive impairment in dementia associated with Parkinson's disease compared with Alzheimer's disease. J Neurol Neurosurg Psychiatry. Oct 2007;78(10):1064-1068.

Hoogland J, van Wanrooij LL, Boel JA, et al. Detecting Mild Cognitive Deficits in Parkinson's Disease: Comparison of Neuropsychological Tests. Mov Disord. Nov 2018;33(11):1750-1759.

Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord. Sep 15 2007;22(12):1689-1707; quiz 1837.

Bjornestad A, Pedersen KF, Tysnes OB, Alves G. Clinical milestones in Parkinson's disease: A 7-year population-based incident cohort study. Parkinsonism Relat Disord. Sep 2017;42:28-33.

Braak H, Rub U, Jansen Steur EN, Del Tredici K, de Vos RA. Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology. Apr 26 2005;64(8):1404-1410.

Wang YX, Zhao J, Li DK, et al. Associations between cognitive impairment and motor dysfunction in Parkinson's disease. Brain Behav. Jun 2017;7(6):e00719.

Hanganu A, Bedetti C, Degroot C, et al. Mild cognitive impairment is linked with faster rate of cortical thinning in patients with Parkinson's disease longitudinally. Brain. Apr 2014;137(Pt 4):1120-1129.

Pereira B, Svenningsson P, Weintraub D, et al. Initial cognitive decline is associated with cortical thinning in early Parkinson disease. Neurology. 2014;82(22):2017-2025.

Gasca-Salas C, Garcia-Lorenzo D, Garcia-Garcia D, et al. Parkinson's disease with mild cognitive impairment: severe cortical thinning antedates dementia. Brain Imaging Behav. Jul 14 2017.

Wen MC, Ng A, Chander RJ, Au WL, Tan LC, Kandiah N. Longitudinal brain volumetric changes and their predictive effects on cognition among cognitively asymptomatic patients with Parkinson's disease. Parkinsonism Relat Disord. May 2015;21(5):483-488.

Kehagia AA, Barker RA, Robbins TW. Cognitive impairment in Parkinson's disease: the dual syndrome hypothesis. Neurodegener Dis. 2013;11(2):79-92.

Robbins TW, Cools R. Cognitive deficits in Parkinson's disease: a cognitive neuroscience perspective. Mov Disord. Apr 15 2014;29(5):597-607.

Calabresi P, Picconi B, Parnetti L, Di Filippo M. A convergent model for cognitive dysfunctions in Parkinson's disease: the critical dopamine-acetylcholine synaptic balance. The Lancet Neurology. 2006;5(11):974-983.

Gratwicke J, Jahanshahi M, Foltynie T. Parkinson's disease dementia: a neural networks perspective. Brain. Jun 2015;138(Pt 6):1454-1476.

Kehagia AA, Barker RA, Robbins TW. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. The Lancet Neurology. 2010;9(12):1200- 1213.

Hirano S, Shinotoh H, Eidelberg D. Functional brain imaging of cognitive dysfunction in Parkinson's disease. J Neurol Neurosurg Psychiatry. Oct 2012;83(10):963-969.

Lee JE, Cho KH, Song SK, et al. Exploratory analysis of neuropsychological and neuroanatomical correlates of progressive mild cognitive impairment in Parkinson's disease. J Neurol Neurosurg Psychiatry. Jan 2014;85(1):7-16.

Gao Y, Nie K, Huang B, et al. Changes of brain structure in Parkinson's disease patients with mild cognitive impairment analyzed via VBM technology. Neurosci Lett. Sep 29 2017;658:121-132.

Williams-Gray CH, Evans JR, Goris A, et al. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain. Nov 2009;132(Pt 11):2958-2969.

Liu G, Locascio JJ, Corvol J-C, et al. Prediction of cognition in Parkinson's disease with a clinical-genetic score: a longitudinal analysis of nine cohorts. The Lancet Neurology. 2017;16(8):620-629.

Lunde KA, Chung J, Dalen I, et al. Association of glucocerebrosidase polymorphisms and mutations with dementia in incident Parkinson's disease. Alzheimers Dement. Oct 2018;14(10):1293-1301.

Maple-Grodem J, Chung J, Lunde KA, et al. Alzheimer disease associated variants in SORL1 accelerate dementia development in Parkinson disease. Neurosci Lett. May 1 2018;674:123-126.

Hughes A, Daniel S, Kilford L, Lees A. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55(3):181-184.

Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. Oct 2015;30(12):1591-1601.

Gelb D, Oliver E, Gilman S. Diagnostic criteria for Parkinson's disease.Arch Neurol. 1999;56(1):33-39.

Kohr S-P, Hsu A. The Pharmacokinetics and Pharmacodynamics of Levodopa in the Treatment of Parkinson's Disease. Current Clinical Pharmacology. 2007;2:234-243.

Xie CL, Zhang YY, Wang XD, et al. Levodopa alone compared with levodopa-sparing therapy as initial treatment for Parkinson's disease: a meta-analysis. Neurol Sci. Aug 2015;36(8):1319-1329.

Bjornestad A, Forsaa EB, Pedersen KF, Tysnes OB, Larsen JP, Alves G. Risk and course of motor complications in a population-based incident Parkinson's disease cohort. Parkinsonism Relat Disord. Jan 2016;22:48-53.

Stathis P, Konitsiotis S, Antonini A. Dopamine agonists early monotherapy for the delay of development of levodopa-induced dyskinesia. Expert Rev. Neurotherapeutics. 2015;15:207-2013.

Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. The Lancet Neurology. 2006;5(8):677-687.

Rabinak C, Nirenberg MJ. Dopamine Agonist Withdrawal Syndrome in Parkinson Disease. Arch Neurol. 2010;67:58-63.

Lee Y, Kim MS, Lee J. Neuroprotective strategies to prevent and treat Parkinson's disease based on its pathophysiological mechanism. Arch Pharm Res. Oct 2017;40(10):1117-1128.

Dietrichs E, Odin P. Algorithms for the treatment of motor problems in Parkinson's disease. Acta Neurol Scand. Nov 2017;136(5):378-385.

Fox SH, Katzenschlager R, Lim SY, et al. International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease. Mov Disord. Aug 2018;33(8):1248-1266.

World Health Organization. International statistical classification of diseases and related health problems (11th Revision). Retrieved from

Dell'Osso B, Altamura AC, Allen A, Marazziti D, Hollander E. Epidemiologic and clinical updates on impulse control disorders: a critical review. Eur Arch Psychiatry Clin Neurosci. Dec 2006;256(8):464-475.

Black DW. Compulsive Buying Disorder Definition, Assessment, Epidemiology and Clinical Management. CNS Drugs. 2001;15(1):17- 27.

Grant JE, Kim SW. Quality of life in kleptomania and pathological gambling. Compr Psychiatry. Jan-Feb 2005;46(1):34-37.

Grant JE, Redden SA, Leppink EW, Odlaug BL, Chamberlain SR. Psychosocial dysfunction associated with skin picking disorder and trichotillomania. Psychiatry Res. May 30 2016;239:68-71.

Robbins T, Clark L. Behavioral addictions. Curr Opin Neurobiol. Sep 25 2014;30C:66-72.

Moore CF, Sabino V, Koob GF, Cottone P. Pathological Overeating: Emerging Evidence for a Compulsivity Construct. Neuropsychopharmacology. Jun 2017;42(7):1375-1389.

Grant JE, Potenza MN, Weinstein A, Gorelick DA. Introduction to behavioral addictions. Am J Drug Alcohol Abuse. Sep 2010;36(5):233- 241.

Grant JE, Atmaca M, Fineberg NA, et al. Impulse control disorders and "behavioural addictions" in the ICD-11. World Psychiatry. Jun 2014;13(2):125-127.

Grant JE, Chamberlain SR. Expanding the definition of addiction: DSM-5 vs. ICD-11. CNS Spectr. Aug 2016;21(4):300-303.

Yau YH, Potenza MN. Gambling disorder and other behavioral addictions: recognition and treatment. Harv Rev Psychiatry. Mar-Apr 2015;23(2):134-146.

Brewer JA, Potenza MN. The neurobiology and genetics of impulse control disorders: relationships to drug addictions. Biochem Pharmacol. Jan 1 2008;75(1):63-75.

Potenza MN, Koran LM, Pallanti S. The relationship between impulse- control disorders and obsessive-compulsive disorder: a current understanding and future research directions. Psychiatry Res. Nov 30 2009;170(1):22-31.

Hollander E, Stein DJ. Clinical Manual of Impulse-Control Disorders. USA: American Psychiatric Association; 2006.

Rosenberg KP, Feder LC. Behavioral Addictions: Criteria, evidence, and treatment. London, UK: Academic Press; 2014.

American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: American Psychiatric Publishing; 2013.

Grant JE, Schreiber LR, Odlaug BL. Phenomenology and treatment of behavioural addictions. Can J Psychiatry. May 2013;58(5):252-259.

Kyrios M, Trotzke P, Lawrence L, et al. Behavioral Neuroscience of Buying-Shopping Disorder: a Review. Current Behavioral Neuroscience Reports. 2018;5(4):263-270.

Kaus SW, Krueger R, Briken P, et al. Compulsive sexual behaviour disorder in the ICD-11. World Psychiatry. 2018;17(1):109-110.

Potenza MN. Clinical neuropsychiatric considerations regarding nonsubstance or behavioral addictions. Dialogues Clin Neurosci. 2017;19:281-292.

Brady S, Duffey P. Impulse control disorder manifesting as hidden sexual self-injury. Pract Neurol. Jun 2015;15(3):226.

Clemm von Hochenberg C, Dressing H. Stealing as an Impulse Control Disorders Associated with Pramipexole - A Case Report from Forensic Psychiatry Practice. . Psychiatr Prax. 2017;44(3):172-174.

Micheli F, Pellene A, Arcushin D, Calzinari A, Farret MS. Pet killing as a manifestation of impulse control disorder secondary to pramipexol. Clin Neuropharmacol. Mar-Apr 2015;38(2):55-56.

Raina G, Cersosimo MG, Micheli F. Zoophilia and impulse control disorder in a patient with Parkinson disease. J Neurol. May 2012;259(5):969-970.

Weintraub D, Hoops S, Shea JA, et al. Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease. Mov Disord. Jul 30 2009;24(10):1461-1467.

Weintraub D, Papay K, Siderowf AD. Screening for impulse control symtpoms in patients with de novo Parkinson disease - A case-control study. Neurology. 2013;80:176-180.

Hodgins DC, Stea JN, Grant JE. Gambling disorders. The Lancet. 2011;378(9806):1874-1884.

Honsi A, Mentzoni RA, Molde H, Pallesen S. Attentional bias in problem gambling: a systematic review. J Gambl Stud. Sep 2013;29(3):359-375.

Nautiyal KM, Okuda M, Hen R, Blanco C. Gambling disorder: an integrative review of animal and human studies. Ann N Y Acad Sci. Apr 2017;1394(1):106-127.

Kessler RC, Hwang I, LaBrie R, et al. DSM-IV pathological gambling in the National Comorbidity Survey Replication. Psychol Med. Sep 2008;38(9):1351-1360.

Romer Thomsen K, Callesen MB, Hesse M, et al. Impulsivity traits and addiction-related behaviors in youth. J Behav Addict. Jun 1 2018;7(2):317-330.

Gyollai A, Griffiths MD, Barta C, et al. The genetics of problem and pathological gambling: a systematic review. Curr Pharm Des. 2014;20(25):3993-3999.

Leeman RF, Potenza MN. A targeted review of the neurobiology and genetics of behavioural addictions: an emerging area of research. Can J Psychiatry. May 2013;58(5):260-273.

Blum K, Braverman ER, Holder JM, et al. The Reward Deficiency Syndrome: A Biogenetic Model for the Diagnosis and Treatment of Impulsive, Addictive and Compulsive Behaviors. Journal of Psychoactive Drugs. 2000;32(sup1):1-112.

Luscher C. The Emergence of a Circuit Model for Addiction. Annu Rev Neurosci. Jul 8 2016;39:257-276.

Volkow ND, Wise RA, Baler R. The dopamine motive system: implications for drug and food addiction. Nat Rev Neurosci. Nov 16 2017;18(12):741-752.

Di Chiara G, Bassareo V. Reward system and addiction: what dopamine does and doesn't do. Curr Opin Pharmacol. Feb 2007;7(1):69-76.

Probst CC, van Eimeren T. The functional anatomy of impulse control disorders. Curr Neurol Neurosci Rep. Oct 2013;13(10):386.

Kraus SW, Voon V, Potenza MN. Should compulsive sexual behavior be considered an addiction? Addiction. Dec 2016;111(12):2097-2106.

Voon V, Mole TB, Banca P, et al. Neural correlates of sexual cue reactivity in individuals with and without compulsive sexual behaviours. PLoS One. 2014;9(7):e102419.

Odlaug BL, Lust K, Schreiber LR, et al. Compulsive sexual behavior in young adults. Ann Clin Psychiatry. Aug 2013;25(3):193-200.

Blum K, Badgaiyan RD, Gold MS. Hypersexuality Addiction and Withdrawal: Phenomenology, Neurogenetics and Epigenetics. Cureus. Oct 12 2015;7(10):e348.

Yau YH, Gottlieb CD, Krasna LC, Potenza MN. Food Addiction: Evidence, Evaluation, and Treatment. In: Rosenberg KP, Feder LC, eds. Behavioal Addictions: Criteria, evidence, and treatment. London, UK: Academic Press; 2014.

Carlier N, Marshe VS, Cmorejova J, Davis C, Muller DJ. Genetic Similarities between Compulsive Overeating and Addiction Phenotypes: A Case for "Food Addiction"? Curr Psychiatry Rep. Dec 2015;17(12):96.

Moore CF, Sabino V, Koob GF, Cottone P. Neuroscience of Compulsive Eating Behavior. Front Neurosci. 2017;11:469.

Di Segni M, Patrono E, Patella L, Puglisi-Allegra S, Ventura R. Animal models of compulsive eating behavior. Nutrients. Oct 22 2014;6(10):4591-4609.

Lejoyeux M, Tassain V, Solomon J, Ades J. Study of compulsive buying in depressed patients. J Clin Psychiatry. Apr 1997;58(4):169- 173.

Maraz A, Griffiths MD, Demetrovics Z. The prevalence of compulsive buying: a meta-analysis. Addiction. Mar 2016;111(3):408-419.

Faber RJ, O'Guinn TC. A Clinical Screener for Compulsive Buying. Journal of Consumer Research. 1992;19(3).

Mueller A, Mitchell JE, Crosby RD, et al. Estimated prevalence of compulsive buying in Germany and its association with sociodemographic characteristics and depressive symptoms. Psychiatry Res. Dec 30 2010;180(2-3):137-142.

Racine E, Kahn T, Hollander E. Compulsive Buying Disorder. In: Rosenberg KP, Feder LC, eds. Behavioral Addictions: Criteria, Evidence, and Treatment. London, UK: Academic Press; 2014.

Algase DL, Moore DH, Vandeweerd C, Gavin-Dreschnack DJ. Mapping the maze of terms and definitions in dementia-related wandering. Aging Ment Health. Nov 2007;11(6):686-698.

Rylander G. Psychoses and the Punding and Choreiform Syndromes in Addiction to Central Stimulant Drugs. Psychiatria, Neurologia, Neurochiurgia. 1972;75:203-212.

Evans AH, Katzenschlager R, Paviour D, et al. Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov Disord. Apr 2004;19(4):397-405.

Schøirring E. Psychopathology Induced by "Speed Drugs". Pharmacology Biochemistry and Behavior. 1981;14:109-122.

Ringdahl JE, Wacker DP, Berg WK, Harding JW. Repetitive Behavior Disorders in Persons with Developmental Disabilities. In: Woods BW, Miltenberger RG, eds. Tic Disorders, Trichotillomania, and Other Repetitive Behavior Disorders. USA: Springer Science+Business Media; 2001.

O'Sullivan JD, Evans AH, Lees A. Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management. CNS Drugs. 2009;32(2):157-170.

Vela L, Martinez Castrillo JC, Garcia Ruiz P, et al. The high prevalence of impulse control behaviors in patients with early-onset Parkinson's disease: A cross-sectional multicenter study. J Neurol Sci. Sep 15 2016;368:150-154.

Rohde K, Riedel O, Lueken U, et al. [Impulsive-compulsive behaviours in a German Parkinson's disease outpatient sample]. Fortschr Neurol Psychiatr. Sep 2013;81(9):503-510.

Callesen MB, Weintraub D, Damholdt MF, Moller A. Impulsive and compulsive behaviors among Danish patients with Parkinson's disease: prevalence, depression, and personality. Parkinsonism Relat Disord. Jan 2014;20(1):22-26.

Rodriguez-Violante M, Gonzalez-Latapi P, Cervantes-Arriaga A, Camacho-Ordonez A, Weintraub D. Impulse control and related disorders in Mexican Parkinson's disease patients. Parkinsonism Relat Disord. Aug 2014;20(8):907-910.

Kim J, Kim M, Kwon do Y, et al. Clinical characteristics of impulse control and repetitive behavior disorders in Parkinson's disease. J Neurol. Feb 2013;260(2):429-437.

Barbeau A. L-dopa therapy in Parkinson's disease: a critical review of nine years' experience. Canada med Assoc J. 1969;101:59-68.

Harvey NS. Serial cognitive profiles in levodopa-induced hypersexuality. Br J Psychiatry. Dec 1988;153:833-836.

O'Brian C, Digiacomo J, Fahn S, Schwarz OA. Mental effects of high- dosage levodopa. Archives of General Psychiatry. 1971;24:61-63.

Goodwin FK. Psychiatric side effects of Levodopa in Man. JAMA - Journal of the American Medical Association. 1971;218(13):1915- 1920.

Fernandez H, Friedman J. Punding on L-Dopa. Movement Disorders. 1999;14(5):836-838.<836::AID-MDS1018>3.0.CO;2-0

A.H. E, A.D. L, Potts J, Appel S, Lees AJ. Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease. Neurology. 2005;65:1570-1574.

Giovannoni G, O'Sullivan JD, Turner K, Manson AJ, Lees AJ. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry. Apr 2000;68(4):423-428.

Molina JA, Sainz-Artiga M, Fraile A, et al. Pathologic Gambling in Parkinson's Disease: A Behavioral Manifestation of Pharmacologic Treatment? Movement Disorders. 2000;15(5):869-872.<869::AID-MDS1016>3.0.CO;2-I

Seedat S, Kesler S, Niehaus DJ, Stein DJ. Pathological gambling behaviour: emergence secondary to treatment of Parkinson's disease with dopaminergic agents. Depress Anxiety. 2000;11(4):185-186.<185::AID-DA8>3.0.CO;2-H

Nirenberg MJ, Waters C. Compulsive eating and weight gain related to dopamine agonist use. Movement Disorders. 2006;21(4):524-529.

Kurlan R. Disabling repetitive behaviors in Parkinson's disease. Mov Disord. Apr 2004;19(4):433-437.

Voon V. Repetition, repetition, and repetition: compulsive and punding behaviors in Parkinson's disease. Mov Disord. Apr 2004;19(4):367-370.

Wolters E, van der Werf YD, van den Heuvel OA. Parkinson's disease- related disorders in the impulsive-compulsive spectrum. J Neurol. Sep 2008;255 Suppl 5:48-56.

Germain V, Marchand A, Bouchard S, Drouin MS, Guay S. Effectiveness of cognitive behavioural therapy administered by videoconference for posttraumatic stress disorder. Cogn Behav Ther. 2009;38(1):42-53.

Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. May 2010;67(5):589-595.

Joutsa J, Martikainen K, Vahlberg T, Voon V, Kaasinen V. Impulse control disorders and depression in Finnish patients with Parkinson's disease. Parkinsonism Relat Disord. Feb 2012;18(2):155-160.

Lim SY, Tan ZK, Ngam PI, et al. Impulsive-compulsive behaviors are common in Asian Parkinson's disease patients: assessment using the QUIP. Parkinsonism Relat Disord. Dec 2011;17(10):761-764.

Tanaka K, Wada-Isoe K, Nakashita S, Yamamoto M, Nakashima K. Impulsive compulsive behaviors in Japanese Parkinson's disease patients and utility of the Japanese version of the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's disease. J Neurol Sci. Aug 15 2013;331(1-2):76-80.

Molde H, Moussavi Y, Kopperud ST, Erga AH, Hansen AL, Pallesen S. Impulse-Control Disorders in Parkinson's Disease: A Meta-Analysis and Review of Case-Control Studies. Front Neurol. 2018;9:330.

Isaias IU, Siri C, Cilia R, De Gaspari D, Pezzoli G, Antonini A. The relationship between impulsivity and impulse control disorders in Parkinson's disease. Mov Disord. Feb 15 2008;23(3):411-415.

Ondo WG, Lai D. Predictors of impulsivity and reward seeking behavior with dopamine agonists. Parkinsonism Relat Disord. 2008;14(1):28-32.

Singh A, Kandimala G, Dewey RB, Jr., O'Suilleabhain P. Risk factors for pathologic gambling and other compulsions among Parkinson's disease patients taking dopamine agonists. J Clin Neurosci. Dec 2007;14(12):1178-1181.

Weintraub D, Siderowf AD, Potenza MN, et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol. Jul 2006;63(7):969-973.

Voon V, Hassan K, Zurowski M, et al. Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology. Jun 13 2006;66(11):1750-1752.

Pontone G, Williams JR, Bassett SS, Marsh L. Clinical features associated with impulse control disorders in Parkinson disease. Neurology. 2006;67:1258-1261.

Voon V, Thomsen T, Miyasaki JM, et al. Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch Neurol. Feb 2007;64(2):212-216.

Nombela C, Rittman T, Robbins TW, Rowe JB. Multiple modes of impulsivity in Parkinson's disease. PLoS One. 2014;9(1):e85747.

Marín-Lahoz J, Pagonabarraga J, Martinez-Horta S, et al. Parkinson's Disease: Impulsivity Does Not Cause Impulse Control Disorders but Boosts Their Severity. Front Psychiatry. 2018;9.

Poletti M, Bonuccelli U. Impulse control disorders in Parkinson's disease: the role of personality and cognitive status. J Neurol. Nov 2012;259(11):2269-2277.

Phu AL, Xu Z, Brakoulias V, et al. Effect of impulse control disorders on disability and quality of life in Parkinson's disease patients. J Clin Neurosci. Jan 2014;21(1):63-66.

Leroi I, Harbishettar V, Andrews M, McDonald K, Byrne EJ, Burns A. Carer burden in apathy and impulse control disorders in Parkinson's disease. Int J Geriatr Psychiatry. Feb 2012;27(2):160-166.

Voon V, Fox SH. Medication-related impulse control and repetitive behaviors in Parkinson disease. Arch Neurol. Aug 2007;64(8):1089- 1096.

Garlovsky JK, Simpson J, Grunewald RA, Overton PG. Impulse control disorders in Parkinson's disease: Predominant role of psychological determinants. Psychol Health. Dec 2016;31(12):1391-1414.

Antonini A, Barone P, Bonuccelli U, Annoni K, Asgharnejad M, Stanzione P. ICARUS study: prevalence and clinical features of impulse control disorders in Parkinson's disease. J Neurol Neurosurg Psychiatry. Apr 2017;88(4):317-324.

Biundo R, Weis L, Abbruzzese G, et al. Impulse control disorders in advanced Parkinson's disease with dyskinesia: The ALTHEA study. Mov Disord. Sep 27 2017.

Sarathchandran P, Soman S, Sarma G, Krishnan S, Kishore A. Impulse control disorders and related behaviors in Indian patients with Parkinson's disease. Mov Disord. Nov 2013;28(13):1901-1902.

Voon V, Sohr M, Lang AE, et al. Impulse control disorders in Parkinson disease: a multicenter case--control study. Ann Neurol. Jun 2011;69(6):986-996.

Voon V, Schoerling A, Wenzel S, et al. Frequency of impulse control behaviours associated with dopaminergic therapy in restless legs syndrome. BMC Neurol. 2011;11:117.

Bancos I, Nannenga MR, Bostwick JM, Silber MH, Erickson D, Nippoldt TB. Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study. Clin Endocrinol (Oxf). Jun 2014;80(6):863-868.

Holman AJ. Impulse control disorder behaviors associated with pramipexole used to treat fibromyalgia. J Gambl Stud. Sep 2009;25(3):425-431.

Soyka M, Huppert D. L-dopa abuse in a patient with former alcoholism. Br J Addict. Jan 1992;87(1):117-118.

Grosset DG, Cardoso F, Lees A. Dopamine Agonists vs Levodopa in Impulse Control Disorders. Arch Neurol. 2011;68(4):544-546.

Cilia R, Siri C, Canesi M, et al. Dopamine dysregulation syndrome in Parkinson's disease: from clinical and neuropsychological characterisation to management and long-term outcome. J Neurol Neurosurg Psychiatry. Mar 2014;85(3):311-318.

Fasano A, Petrovic I. Insights into pathophysiology of punding reveal possible treatment strategies. Mol Psychiatry. Jun 2010;15(6):560-573.

Antonini A, Siri C, Santangelo G, et al. Impulsivity and compulsivity in drug-naive patients with Parkinson's disease. Mov Disord. Feb 15 2011;26(3):464-468.

Claassen DO, van den Wildenberg WP, Ridderinkhof KR, et al. The risky business of dopamine agonists in Parkinson disease and impulse control disorders. Behav Neurosci. Aug 2011;125(4):492-500.

Housden CR, O'Sullivan SS, Joyce EM, Lees AJ, Roiser JP. Intact reward learning but elevated delay discounting in Parkinson's disease patients with impulsive-compulsive spectrum behaviors. Neuropsychopharmacology. Oct 2010;35(11):2155-2164.

Voon V, Gao J, Brezing C, et al. Dopamine agonists and risk: impulse control disorders in Parkinson's disease. Brain. May 2011;134(Pt 5):1438-1446.

Clark CA, Dagher A. The role of dopamine in risk taking: a specific look at Parkinson's disease and gambling. Front Behav Neurosci. 2014;8:196.

Vriend C, Nordbeck AH, Booij J, et al. Reduced dopamine transporter binding predates impulse control disorders in Parkinson's disease. Mov Disord. Jun 2014;29(7):904-911.

Biundo R, Weis L, Facchini S, et al. Patterns of cortical thickness associated with impulse control disorders in Parkinson's disease. Mov Disord. Apr 15 2015;30(5):688-695.

Carriere N, Lopes R, Defebvre L, Delmaire C, Dujardin K. Impaired corticostriatal connectivity in impulse control disorders in Parkinson disease. Neurology. May 26 2015;84(21):2116-2123.

Pellicano C, Niccolini F, Wu K, et al. Morphometric changes in the reward system of Parkinson's disease patients with impulse control disorders. J Neurol. Dec 2015;262(12):2653-2661.

Tessitore A, Santangelo G, De Micco R, et al. Resting-state brain networks in patients with Parkinson's disease and impulse control disorders. Cortex. Jun 24 2017;94:63-72.

Tessitore A, Santangelo G, De Micco R, et al. Cortical thickness changes in patients with Parkinson's disease and impulse control disorders. Parkinsonism Relat Disord. Mar 2016;24:119-125.

De Micco R, Russo A, Tedeschi G, Tessitore A. Impulse Control Behaviors in Parkinson's Disease: Drugs or Disease? Contribution From Imaging Studies. Front Neurol. 2018;9:893.

Martini A, Dal Lago D, Edelstyn NMJ, Grange JA, Tamburin S. Impulse Control Disorder in Parkinson's Disease: A Meta-Analysis of Cognitive, Affective, and Motivational Correlates. Frontiers in Neurology. 2018;9.

Vriend C, Pattij T, van der Werf YD, et al. Depression and impulse control disorders in Parkinson's disease: two sides of the same coin? Neurosci Biobehav Rev. Jan 2014;38:60-71.

Mack J, Okai D, Brown RG, et al. The Role of Self-Awareness and Cognitive Dysfunction in Parkinson's Disease With and Without Impulse-Control Disorder. J Neuropsychiatry Clin Neurosci. 2013;25(2):141-149.

Papapetropoulos S, Mash DC. Psychotic symptoms in Parkinson's disease. From description to etiology. J Neurol. Jul 2005;252(7):753- 764.

Voon V, Napier TC, Frank MJ, et al. Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease: an update. Lancet Neurol. Mar 2017;16(3):238-250.

Hinkle JT, Perepezko K, Rosenthal LS, et al. Markers of impaired motor and cognitive volition in Parkinson's disease: Correlates of dopamine dysregulation syndrome, impulse control disorder, and dyskinesias. Parkinsonism Relat Disord. Nov 21 2017.

Santangelo G, Raimo S, Barone P. The relationship between Impulse Control Disorders and cognitive dysfunctions in Parkinson's Disease: A meta-analysis. Neurosci Biobehav Rev. Jun 2017;77:129-147.

Bentivoglio AR, Baldonero E, Ricciardi L, De Nigris F, Daniele A. Neuropsychological features of patients with Parkinson's disease and impulse control disorders. Neurol Sci. Jul 2013;34(7):1207-1213.

Goetz CG, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord. Jan 2007;22(1):41-47.

American Psychiatric Association. Diagnostic and Statistical manual of Mental Disorders: DSM-IV-TR. Washington DC: American Psychiatric Association; 2000.

Voon V, Hassan K, Zurowski M, et al. Prevalence of repetitative and reward seeking behaviros in PD. Neurology. 2006;67:1254-1257.

Okai D, Askey-Jones S, Mack J, et al. Parkinson's Impulse-Control Scale for the Severity Rating of Impulse-Control Behaviors in Parkinson's Disease: A Semistructured Clinical Assessment Tool. Mov Disord Clin Pract. Sep-Oct 2016;3(5):494-499.

Grant JE. Impulse Control Disorders: A Clinician's Guide to Understanding and Treating Behavioral Addictions. New York: WW Norton and Company; 2008.

Chamberlain SR, Grant JE. Minnesota Impulse Disorders Interview (MIDI): Validation of a structured diagnostic clinical interview for impulse control disorders in an enriched community sample. Psychiatry Res. Jul 2018;265:279-283.

Cossu G, Rinaldi R, Colosimo C. The rise and fall of impulse control behavior disorders. Parkinsonism Relat Disord. Jan 2018;46 Suppl 1:S24-S29.

O'Callaghan C, Bertoux M, Hornberger M. Beyond and below the cortex: the contribution of striatal dysfunction to cognition and behaviour in neurodegeneration. J Neurol Neurosurg Psychiatry. Apr 2014;85(4):371-378.

Erga AH, Dalen I, Ushakova A, et al. Dopaminergic and Opioid Pathways Associated with Impulse Control Disorders in Parkinson's Disease. Frontiers in Neurology. 2018;9.

Kraemmer J, Smith K, Weintraub D, et al. Clinical-genetic model predicts incident impulse control disorders in Parkinson's disease. J Neurol Neurosurg Psychiatry. Apr 13 2016.

Martini A, Dal Lago D, Edelstyn NMJ, Salgarello M, Lugoboni F, Tamburin S. Dopaminergic Neurotransmission in Patients With Parkinson's Disease and Impulse Control Disorders: A Systematic Review and Meta-Analysis of PET and SPECT Studies. Front Neurol. 2018;9:1018.

Lee JY, Lee EK, Park SS, et al. Association of DRD3 and GRIN2B with impulse control and related behaviors in Parkinson's disease. Mov Disord. Sep 15 2009;24(12):1803-1810.

Blum K, Sheridan P, Wood R, et al. The D2 dopamine receptor gene as a determinant of reward deficiency syndrome. JOURNAL OF THE ROYAL SOCIETY OF MEDICINE. 1996;89(396-400).

Seeman P. Parkinson's disease treatment may cause impulse-control disorder via dopamine D3 receptors. Synapse. Apr 2015;69(4):183-189.

Cormier-Dequaire F, Bekadar S, Anheim M, et al. Suggestive association between OPRM1 and impulse control disorders in Parkinson's disease. Mov Disord. Dec 2018;33(12):1878-1886.

Cilia R, Benfante R, Asselta R, et al. Tryptophan hydroxylase type 2 variants modulate severity and outcome of addictive behaviors in Parkinson's disease. Parkinsonism Relat Disord. Aug 2016;29:96-103.

Vallelunga A, Flaibani R, Formento-Dojot P, Biundo R, Facchini S, Antonini A. Role of genetic polymorphisms of the dopaminergic system in Parkinson's disease patients with impulse control disorders. Parkinsonism Relat Disord. May 2012;18(4):397-399.

Zainal Abidin S, Tan EL, Chan SC, et al. DRD and GRIN2B polymorphisms and their association with the development of impulse control behaviour among Malaysian Parkinson's disease patients. BMC Neurol. 2015;15:59.

Hoenicka J, Garcia-Ruiz PJ, Ponce G, et al. The addiction-related gene ANKK1 in Parkinsonian patients with impulse control disorder. Neurotox Res. Apr 2015;27(3):205-208.

Krishnamoorthy S, Rajan R, Banerjee M, et al. Dopamine D3 receptor Ser9Gly variant is associated with impulse control disorders in Parkinson's disease patients. Parkinsonism Relat Disord. Sep 2016;30:13-17.

Castro-Martinez XH, Garcia-Ruiz PJ, Martinez-Garcia C, et al. Behavioral addictions in early-onset Parkinson disease are associated with DRD3 variants. Parkinsonism Relat Disord. Jan 12 2018.

Lee JY, Jeon BS, Kim HJ, Park SS. Genetic variant of HTR2A associates with risk of impulse control and repetitive behaviors in Parkinson's disease. Parkinsonism Relat Disord. Jan 2012;18(1):76-78.

Charbogne P, Kieffer BL, Befort K. 15 years of genetic approaches in vivo for addiction research: Opioid receptor and peptide gene knockout in mouse models of drug abuse. Neuropharmacology. Jan 2014;76 Pt B:204-217.

Darcq E, Kieffer BL. Opioid receptors: drivers to addiction? Nat Rev Neurosci. Aug 2018;19(8):499-514.

Fontenelle LF, Oostermeijer S, Harrison BJ, Pantelis C, Yucel M. Obsessive-compulsive disorder, impulse control disorders and drug addiction: common features and potential treatments. Drugs. May 7 2011;71(7):827-840.

Cho S, Kim K, Kim YJ, et al. Joint identification of multiple genetic variants via elastic-net variable selection in a genome-wide association analysis. Ann Hum Genet. Sep 01 2010;74(5):416-428.

Ueki M, Tamiya G, Alzheimer's Disease Neuroimaging I. Smooth- Threshold Multivariate Genetic Prediction with Unbiased Model Selection. Genet Epidemiol. Apr 2016;40(3):233-243.

Waldmann P, Meszaros G, Gredler B, Fuerst C, Solkner J. Evaluation of the lasso and the elastic net in genome-wide association studies. Front Genet. 2013;4:270.

Yi H, Breheny P, Imam N, Liu Y, Hoeschele I. Penalized multimarker vs. single-marker regression methods for genome-wide association studies of quantitative traits. Genetics. Jan 2015;199(1):205-222.

Smith KM, Xie SX, Weintraub D. Incident impulse control disorder symptoms and dopamine transporter imaging in Parkinson disease. J Neurol Neurosurg Psychiatry. Nov 3 2015.

Bastiaens J, Dorfman BJ, Christos PJ, Nirenberg MJ. Prospective cohort study of impulse control disorders in Parkinson's disease. Mov Disord. Mar 2013;28(3):327-333.

Mamikonyan E, Siderowf AD, Duda JE, et al. Long-term follow-up of impulse control disorders in Parkinson's disease. Mov Disord. Jan 2008;23(1):75-80.

Siri C, Cilia R, Reali E, et al. Long-term cognitive follow-up of Parkinson's disease patients with impulse control disorders. Mov Disord. Apr 15 2015;30(5):696-704.

Corvol JC, Artaud F, Cormier-Dequaire F, et al. Longitudinal analysis of impulse control disorders in Parkinson disease. Neurology. Jul 17 2018;91(3):e189-e201.

Joutsa J, Martikainen K, Vahlberg T, Kaasinen V. Effects of dopamine agonist dose and gender on the prognosis of impulse control disorders in Parkinson's disease. Parkinsonism Relat Disord. Dec 2012;18(10):1079-1083.

Zhang S, Dissanayaka NN, Dawson A, et al. Management of impulse control disorders in Parkinson's disease. Int Psychogeriatr. Oct 2016;28(10):1597-1614.

Papay K, Xie SX, Stern M, et al. Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study. Neurology. Aug 26 2014;83(9):826-833.

Kehagia AA, Housden CR, Regenthal R, et al. Targeting impulsivity in Parkinson's disease using atomoxetine. Brain. Jul 2014;137(Pt 7):1986- 1997.

Ramirez-Zamora A, Gee L, Boyd J, Biller J. Treatment of impulse control disorders in Parkinson's disease: Practical considerations and future directions. Expert Rev Neurother. 2016;16(4):389-399.

Rosenberg KP, Feder LC. Behavioral Addictions - Criteria, Evidence and Treatment. San Diego, US: Academic Press; 2014.

Okai D, Askey-Jones S, Samuel M, David AS, Brown RG. Predictors of response to a cognitive behavioral intervention for impulse control behaviors in Parkinson's disease. Mov Disord. Apr 15 2015;30(5):736- 739.

Okai D, Askey-Jones S, Samuel M, et al. Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers. Neurology. Feb 2013;80(9):792-799.

Fahn S, Elton R. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden C, Calne D, et al, eds. Recent development in Parkinson's disease. Florham Park, NJ: MacMillan Health Care Information; 1987:153-163.

Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. May 1967;17(5):427-442.

Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.

Leentjens AF, Verhey FR, Lousberg R, Spitsbergen H, Wilmink FW. The validity of the Hamilton and Montgomery-Asberg depression rating scales as screening and diagnostic tools for depression in Parkinson's disease. Int J Geriatr Psychiatry. 2000;15(7):644-649.<644::AID-GPS167>3.0.CO;2-L

Schrag A, Barone P, Brown RG, et al. Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord. Jun 15 2007;22(8):1077-1092.

Suzuki A, Aoshima T, Fukasawa T, et al. A three-factor model of the MADRS in major depressive disorder. Depress Anxiety. 2005;21(2):95- 97.

Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology. May 1997;48(5 Suppl 6):S10-16.

Murray JW. A new method for measuring daytime sleepiness: The Epsworth Sleepiness scale. SLEEP. 1991;14(6):540-545.

Chaudhuri KR, Pal S, DiMarco A, et al. The Parkinson's disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson's disease. J Neurol Neurosurg Psychiatry. Dec 2002;73(6):629-635.

Folstein MF, Folstein SE, McHugh PR. Mini mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198.

Benton AL, Hamsher KD. Multilingual Aphasia Examination. Iowa City, IA: AJA Associates; 1989.

Golden CJ, Freshwater SM. The Stroop Color and Word Test. Wood Dale, IL: The Stoelting Company; 1998.

Delis DC KJ, Ober BA. . CVLT-II. California Verbal Learning Test. Second Edition. Adult Version. San Antonio, TX: The Psychological Corporation: Harcourt Assessment, Inc; 2000.

Warrington EK, James M. The Visual Object and Space Perception Battery. Bury St Edmunds: Thames Valley Test Company; 1991.

Cohen P, Cohen J, Aiken LS, West SG. The Problem of Units and the Circumstance for POMP. Multivariate Behavioral Research. 1999;34(3):315-346.

Moeller J. A word on standardization in longitudinal studies: don't. Front Psychol. 2015;6:1389.

Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain. Apr 2002;125:861-870.

Broeders M, de Bie RM, Velseboer DC, Speelman JD, Muslimovic D, Schmand B. Evolution of mild cognitive impairment in Parkinson disease. Neurology. Jul 23 2013;81(4):346-352.

Domellof ME, Ekman U, Forsgren L, Elgh E. Cognitive function in the early phase of Parkinson's disease, a five-year follow-up. Acta Neurol Scand. Aug 2015;132(2):79-88.

Morrell CH, Brant LJ, Ferrucci L. Model choice can obscure results in longitudinal studies. J Gerontol A Biol Sci Med Sci. Feb 2009;64(2):215-222.

Perez-Lloret S, Rey MV, Fabre N, et al. Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease. Clin Neuropharmacol. Nov-Dec 2012;35(6):261-265.

Valenca GT, Glass PG, Negreiros NN, et al. Past smoking and current dopamine agonist use show an independent and dose-dependent association with impulse control disorders in Parkinson's disease. Parkinsonism Relat Disord. Jul 2013;19(7):698-700.

Hinkle JT, Perepezko K, Rosenthal LS, et al. Markers of impaired motor and cognitive volition in Parkinson's disease: Correlates of dopamine dysregulation syndrome, impulse control disorder, and dyskinesias. Parkinsonism Relat Disord. May 2 2018.

Castrioto A, Funkiewiez A, Debu B, et al. Iowa gambling task impairment in Parkinson's disease can be normalised by reduction of dopaminergic medication after subthalamic stimulation. J Neurol Neurosurg Psychiatry. May 23 2014.

Piray P, Zeighami Y, Bahrami F, Eissa AM, Hewedi DH, Moustafa AA. Impulse control disorders in Parkinson's disease are associated with dysfunction in stimulus valuation but not action valuation. J Neurosci. Jun 4 2014;34(23):7814-7824.

Girard R, Obeso I, Thobois S, et al. Wait and you shall see: sexual delay discounting in hypersexual Parkinson's disease. Brain. 2018;In press.

Castrioto A, Thobois S, Carnicella S, Maillet A, Krack P. Emotional manifestations of PD: Neurobiological basis. Mov Disord. Aug 2016;31(8):1103-1113.

Blum K, Oscar-Berman M, Demetrovics Z, Barh D, Gold MS. Genetic Addiction Risk Score (GARS): molecular neurogenetic evidence for predisposition to Reward Deficiency Syndrome (RDS). Mol Neurobiol. Dec 2014;50(3):765-796.

Meyer GM, Spay C, Laurencin C, Ballanger B, Sescousse G, Boulinguez P. Functional imaging studies of Impulse Control Disorders in Parkinson's disease need a stronger neurocognitive footing. Neurosci Biobehav Rev. Jan 9 2019.

Cover for Impulse Control Disorders in Parkinson’s disease
February 29, 2020